Navigation Links
Sirion Therapeutics Announces Positive Phase III Results for Difluprednate
Date:10/25/2007

ng pain as measured using the Visual Analogue Scale.

Recent studies in post-operative inflammation have used "clinical cure" at Day 15 as the primary endpoint. In these studies, clinical cure was defined as having 5 anterior chamber cells or less and a flare score of zero. Applying these criteria to our data, at Day 15, 73% of subjects on the difluprednate BID regimen reached clinical cure versus 27% of subjects in the placebo group, for a treatment effect of 46% (p<0.0001). In the difluprednate QID group, 71% of subjects reached clinical cure at Day 15.

Difluprednate was well tolerated with few treatment related adverse events. Of particular note, mean intraocular pressure (IOP) for all study groups remained within the normal range throughout the trial. Three subjects (3%) in the BID group, three subjects (3%) in the QID group, and two subjects (1%) in the placebo group met the criterion for a clinically significant rise in IOP, defined as an increase of greater than 10 mmHg from baseline combined with a peak pressure of more than 21 mmHg at any time point during the study period.

The analysis demonstrated comparable clinical efficacy and acceptable safety profiles for both BID and QID dosing of difluprednate.

"These are extremely robust data," said Dr. Michael Korenfeld, an ophthalmologist with Comprehensive Eye Care in Washington, Missouri who was an investigator in the trial. "Being able to treat ocular inflammatory disease with a more convenient dosing regimen and having the potential to offer rapid resolution of inflammation after ocular surgery would represent a meaningful advance for patients."

"Sirion is very excited about these results. When we started this program, we felt that difluprednate had the potential to be a major step forward in the control of ocular inflammation. These results met our highest expectations" said Barry Butler, President and CEO of Sirion. "We look forward to bringing this important new treatment opti
'/>"/>

SOURCE Sirion Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Sirion Therapeutics Announces Clinical Data to be Presented at the 2007 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
11. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 /PRNewswire-iReach/ -- "United States General ... key market data on the United ... report provides value, in millions of ... within market categories – Bronchoscopes, Laryngoscopes, ... Gastroscopes, Duodenoscopes, Laparoscopes, Hysteroscopes, Sinuscopes, Resectoscopes, ...
(Date:9/19/2014)... CHICAGO, Ill. , Sept. 19, 2014  The ... ABBV ) declared a quarterly cash dividend of $0.42 ... payable Nov. 17, 2014 to stockholders of record at ... About AbbVie AbbVie is a global, research-based biopharmaceutical ... company,s mission is to use its expertise, dedicated people ...
(Date:9/19/2014)... 19, 2014  4WEB Medical announces the formal launch ... ankle osteotomy implants on the market today at ... meeting in Chicago .  The Osteotomy ... osteotomy needs with 74 size options included in one ... of only 15 to 18 implant sizes, which limited ...
Breaking Medicine Technology:United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 54WEB Medical Unveils 3D-Printed Osteotomy Truss System 2
... Ga. and TRENTON, N.J., April 18, 2012 Kimberly-Clark ... cleanrooms and laboratories, and TerraCycle, a leading recycler, today ... and laboratory garment recycling initiative to include a pilot ... the program,s first six months. Since the ...
...  UCB, a leading biopharmaceutical company committed to the development ... sets of key epilepsy data at the 64th Annual ... New Orleans from April 21-28.  The data comprise several ... Vimpat® (lacosamide) C-V, including updated health-related quality of life ...
Cached Medicine Technology:Kimberly-Clark Professional* and TerraCycle Expand Industry's First Cleanroom and Laboratory Garment Recycling Initiative to Include Pilot Program for Gloves 2Kimberly-Clark Professional* and TerraCycle Expand Industry's First Cleanroom and Laboratory Garment Recycling Initiative to Include Pilot Program for Gloves 3Kimberly-Clark Professional* and TerraCycle Expand Industry's First Cleanroom and Laboratory Garment Recycling Initiative to Include Pilot Program for Gloves 4UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 2UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 3UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 4UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 5UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 6UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 7UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 8UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 9
(Date:9/19/2014)... AZ (PRWEB) September 19, 2014 Hastings and ... 30 years in the industry, announces a record number of ... handles a wide variety of serious injury cases as well ... along with dog bite related accident cases and others. Having ... and Hastings has stood the test of time when it ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Visiting Nurse ... of home health care, hospice and palliative care and ... ring the Opening Bell yesterday at the New York ... Jersey philanthropist and social entrepreneur to care for immigrant ... Group has always worked to meet the urgent healthcare ...
(Date:9/19/2014)... 19, 2014 Boston Scientific Corp. has ... ( http://www.transvaginalmeshlawsuithelp.com/ ) that is scheduled to go ... Liebhard LLP reports. According to a Motion ... company asserts that claims involving its Solyx pelvic mesh ... Remedies Code, a section of which shields manufacturers ...
(Date:9/19/2014)... Your brain structure could help predict how willing you are ... at Yale University found those with greater volume in a ... be more likely to engage in risky behavior than people ... funded by the U.S. National Institute on Aging, involved two ... Northeast. The researchers sought to determine how brain structure influences ...
(Date:9/19/2014)... Although there is mounting evidence that muscle-strength training ... adults in the United States don,t engage in ... Less than one-quarter of adults over 45 ... of Health and Human Services, the study found. ... and fitness and staying independent, researchers advised. Muscle-strengthening ...
Breaking Medicine News(10 mins):Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4Health News:Brain Structure Might Help Predict Risky Behavior 2Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2
... Interfere with Prescribed TherapiesSACRAMENTO, Calif., May 11 The ... a national network of over 250 physicians with the ... approved medical treatments and therapies, today cited a recent ... a large number of physicians believe insurance companies are ...
... announced today that for the quarter ended March 31, 2009, it ... share, on revenues of $5.2 million compared to a net loss ... $5.2 million in the previous year. The loss from continuing operations ... to income of $3.2 million for the same period in 2008. ...
... 11, 2009; 3 pm Central Daylight Time) Many ... into the office complaining of chest pain, undergoes a stress ... results suggest coronary artery disease, a condition in which plaque ... for an angiogram to look at the coronary arteries and ...
... available in French . , Montreal, May ... not have been dealt an equal hand. The latest study ... McGill University Health Centre and McGill University, shows that women ... the production of estrogen by females could have a beneficial ...
... Trust Incorporated (NYSE: HR ) today announced results ... from operations ("FFO") per diluted common share for the three ... for the three months ended March 31, 2008. FFO ... three months ended March 31, 2009, before the recognition of ...
... (NYSE: HR ) today announced its common stock ... This dividend, in the amount of $0.385 per share, is ... May 22, 2009. The total dividend of $22.8 million ... in accordance with GAAP. The Company,s cash flow statement ...
Cached Medicine News:Health News:Alliance for Patient Access Wants Health Care Code of Conduct 2Health News:Westaim announces 2009 first quarter results 2Health News:Westaim announces 2009 first quarter results 3Health News:Study: Women with hard to diagnose chest pain symptoms at higher risk for cardiovascular events 2Health News:Study: Women with hard to diagnose chest pain symptoms at higher risk for cardiovascular events 3Health News:Equality of the sexes? Not always when it comes to biology 2Health News:Healthcare Realty Trust Announces First Quarter Results 2Health News:Healthcare Realty Trust Announces First Quarter Results 3Health News:Healthcare Realty Trust Announces First Quarter Results 4Health News:Healthcare Realty Trust Announces First Quarter Results 5Health News:Healthcare Realty Trust Announces First Quarter Results 6Health News:Healthcare Realty Trust Announces First Quarter Results 7Health News:Healthcare Realty Trust Announces First Quarter Results 8Health News:Healthcare Realty Trust Announces First Quarter Results 9Health News:Healthcare Realty Trust Announces First Quarter Dividend 2Health News:Healthcare Realty Trust Announces First Quarter Dividend 3Health News:Healthcare Realty Trust Announces First Quarter Dividend 4
... features including aspiration holes and additional ... procedures requiring precise dissection with decreased ... suction demands. ,Flexible design options ... nonretractable electrodes and multiple tip designs. ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
Medicine Products: